
Goldman Sachs hosted a meeting with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025).
The analyst maintains the Buy rating with a price target of $33.

Goldman Sachs hosted a meeting with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025).
The analyst maintains the Buy rating with a price target of $33.